Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18739966 | 0.94 | PTGER4 (0.48) | PTGER4PTGER2ALDH1A1KDM4EGAA | |
| SCHEMBL18740150 | 0.88 | TDP1 (0.42) | ALDH1A1KDM4EKMT2AMEN1FAAH | |
| SCHEMBL18740303 | 0.88 | KDM4E (0.40) | ALDH1A1KDM4EFAAHSIGMAR1LMNA | |
| SCHEMBL18758706 | 0.88 | ALDH1A1 (0.42) | PTGER4PTGER2ALDH1A1KDM4EGAA | |
| SCHEMBL18740312 | 0.84 | PTGER4 (0.51) | PTGER4PTGER2ALDH1A1KMT2AMEN1 | |
| SCHEMBL18739995 | 0.84 | GRIA2 (0.40) | SIGMAR1LMNAKCNH2SMN1; SMN2 | |
| SCHEMBL20539521 | 0.83 | PTGER4 (0.41) | PTGER4PTGER2ALDH1A1KMT2AMEN1 | |
| SCHEMBL18740059 | 0.83 | PTGER4 (0.61) | PTGER4PTGER2 | |
| SCHEMBL18740057 | 0.83 | PTGER4 (0.61) | PTGER4PTGER2 | |
| SCHEMBL18740258 | 0.83 | CYP2C9 (0.43) | ALDH1A1KDM4EKMT2AMEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| CN-108473497-B | EP4 antagonists | 卫材R&D 管理有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20180305362-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-3362454-A1 | EP4 ANTAGONISTS | Eisai R&D Management Co., Ltd. (JP) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305362-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ALDH1A1 956/4885 |
| US-10316040-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ALDH1A1 956/4885 |
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ALDH1A1 956/4885 |
| US-20190315754-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ALDH1A1 956/4885 |
| US-20210347779-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ALDH1A1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.